Previous 10 | Next 10 |
home / stock / kttaw / kttaw news
- The Glimpse Group is a Virtual Reality and Augmented Reality platform company - Partnership will allow Pasithea to co-develop VR environments for patients with psychiatric disorders MIAMI BEACH, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KT...
-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy, and other psychiatric treatments, including repeated transcranial magnetic stimulation (“rTMS ...
MIAMI BEACH, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological dis...
MIAMI BEACH, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders...
MIAMI BEACH, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological dis...
MIAMI BEACH, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological dis...
-- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals -- -- Expansion to additional U.S. cities in coming months -- MIAMI BEACH, Fla., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Pasit...
MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological di...
MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological di...
MIAMI BEACH, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological dis...
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Warrant Company Name:
KTTAW Stock Symbol:
NASDAQ Market:
Pasithea Therapeutics Corp. Warrant Website:
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...
-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib -- -- PAS-004 shows superior activity versus selumetinib and...
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the tr...